BTAI
BioXcel Therapeutics, Inc.NASDAQHealthcare$1.18-3.39%ClosedMarket Cap: $28.7M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.15
P/S
43.24
EV/EBITDA
-1.99
DCF Value
$-7.83
FCF Yield
-207.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
51.2%
Operating Margin
-7796.6%
Net Margin
-10887.4%
ROE
73.1%
ROA
-155.6%
ROIC
-314.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $256.0K | 58.6% | $-10.2M | $-12.5M | $-1.03 | — |
| FY 2025 | $642.0K | 27.7% | $-49.7M | $-69.9M | $-5.73 | — |
| Q3 2025 | $98.0K | 12.2% | $-13.9M | $-30.9M | $-2.18 | — |
| Q2 2025 | $120.0K | 10.8% | $-15.9M | $-19.2M | $-2.45 | — |
| Q1 2025 | $168.0K | 91.7% | $-10.1M | $-7.3M | $-1.50 | — |
| Q4 2024 | $366.0K | -127.3% | $-10.5M | $-10.9M | $-3.57 | — |
| FY 2024 | $2.3M | 5.4% | $-67.2M | $-59.6M | $-23.51 | — |
| Q3 2024 | $214.0K | -446.7% | $-15.3M | $-13.7M | $-5.15 | — |
| Q2 2024 | $1.1M | 94.4% | $-17.3M | $-8.3M | $-3.30 | — |
| Q1 2024 | $582.0K | 72.9% | $-23.9M | $-26.8M | $-13.89 | — |
| Q4 2023 | $376.0K | -89.9% | $-19.9M | $-22.3M | $-12.09 | — |
| FY 2023 | $1.4M | 8.7% | $-171.8M | $-179.1M | $-98.35 | — |